In the antiviral field, HMOs rely on two main mechanisms to exert their effects: first, due to their similar structure to cell surface glycans, HMOs can act as soluble decoy receptors to prevent early viral infections, including norovirus and rotavirus; second, HMOs bind with cell surface receptors to block viral attachment (Figure 6). This evidence concerns the gene CD177 and viral infectious disease.